At a glance
- Originator Roche
- Class Neuroprotectants; Small molecules
- Mechanism of Action Kynurenine 3-monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 16 Dec 2003 No development reported - Preclinical for Neurological disorders (Prevention) in Switzerland (unspecified route)
- 29 Aug 2000 Preclinical development for Neurological disorders (Prevention) in Switzerland (Unknown route)